U.S. researchers say promising new medicines are headed to the market that can help overcome increasing resistance to some HIV therapies.
The annual Conference on Retroviruses and Opportunistic Infections in Los Angeles revealed several promising drugs -- including Merck & Co.'s MK-518, Pfizer Inc.'s maraviroc and Johnson & Johnson's TMC125 -- The Wall Street Journal reported.
The three drugs are heading for review by the Food and Drug Administration and could be on the market by the end of 2007, the newspaper said.
Doctors say tens of thousands of HIV patients in the United States are infected with viruses that have become resistant to at least one class of HIV drug. Some patients who have fought HIV for years have run through the roughly two dozen drugs available, the newspaper said.
Copyright 2007 by United Press International
Related stories:
Scientists identify genetic link that may neutralize HIV
Scientists from the Gladstone Institute of Virology and Immunology (GIVI) and the National Institutes of Allergy and Infectious Diseases (NIAID) have identified a gene that may influence the production of antibodies that neutralize HIV. This new information will likely spur a new approach for making an HIV vaccine that elicits neutralizing antibodies. Neutralizing antibodies, once produced in the host, can attack and checkmate an infecting virus. The research was reported in the September 5 issue of
Science.
ABC-transporters expressed on endothelial cell membranes efflux anti-HIV drugs
Researchers at Tulane University Medical Center in New Orleans (USA) have discovered that drug-efflux pumps, belonging to the ATP-binding cassette (ABC) transporter family, are constitutively expressed on vascular endothelial cells. Transcripts for several different ABC-transporters, e.g. MDR-1 (P-gp) and MRPs, were detected in endothelial cells, obtained from brain, aortic artery, pulmonary artery, dermal microvessels and umbilical veins.
Victims of Britain's tainted blood scandal speak
(AP) -- Robert Mackie trembles with rage when he describes how he and his wife were kept in the dark about his HIV infection - and how doctors published his medical data in journals years before they gave him the devastating news.
Operations research promises continued gains for HIV treatment in resource-limited countries
In the past 10 years, the global campaign to expand treatment for millions of people with AIDS living in resource-limited countries, especially in sub-Saharan Africa, has gained substantial commitments in public and private financing, and has made major strides in making treatment available to those who need it. A new collaborative study by researchers at Weill Cornell Medical College and the Clinton Foundation HIV/AIDS Initiative explores how to combine engineering science with medical care to guarantee the long-term success of these treatment programs.
Chemical liberated by leaky gut may allow HIV to infect the brain
In up to 20 percent of people infected with HIV, the virus manages to escape from the bloodstream and cross into the brain, resulting in HIV-associated dementia and other cognitive disorders. Now, scientists at the Albert Einstein College of Medicine of Yeshiva University have found strong evidence that a component of the cell walls of intestinal bacteria—a chemical present in high levels in the blood of HIV-infected people—helps HIV to penetrate the usually-impregnable blood brain barrier (BBB). The findings, published in the August issue of the
Journal of Virology, could lead to strategies for preventing HIV from entering the brain and causing serious complications.
Extensively drug-resistant tuberculosis found in California
In the first statewide study of extensively drug-resistant tuberculosis (XDR TB) in the United States, California officials have identified 18 cases of the dangerous and difficult-to-treat disease between 1993 and 2006, and 77 cases that were one step away from XDR TB. The study appears in the August 15 issue of
Clinical Infectious Diseases, now available online.
Study offers new insight on HIV transmission risk of men who have sex with men
Approximately half of all new HIV infections in the United States result from the sexual risk behaviors of men who have sex with men. Now, a new study led by a researcher at The Miriam Hospital provides additional insight into which of these men are most likely to transmit HIV to others, potentially paving the way for the development of more targeted prevention programs.
Comprehensive treatment of extensively drug-resistant TB works, study finds
The death sentence that too often accompanies a diagnosis of extensively drug-resistant tuberculosis (XDR-TB) can be commuted if an individualized outpatient therapy program is followed – even in countries with limited resources and a heavy burden of TB.